Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 264

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 264
---
 the necessary expertise and qualifications to analyze foreign companies and their business structures and strategies, and more specifically, to analyze them within the context of the regulatory environments pharmaceutical research and development and distribution of medical device products (as in the case of OSR Holdings’ subsidiary RMC). As none of OSR Holdings’ subsidiaries, their businesses and customers are in the US, BLAC came to the decision that it should expand its search to look for valuation consulting companies with global exposure and experience, with a strong emphasis in the area of biopharmaceuticals, and informed OSR Holdings members of this decision. May 22, 2023 At OSR Holdings’ weekly Monday morning meeting on May 22, 2023, Mr. Hwang suggested to OSR Holdings that BLAC would report to the BLAC Board with the following items: 1) a proposed Non -BindingLetter of Intent, 2) Business Combination Timeline (including potential need to request BLAC stockholder approval to 156 extend the period for completion of the Business Combination), 3) Corporate slides of OSR Holdings, and 4) third party valuation reports on Vaximm (dated December 5, 2022) and Darnatein (dated July 2022) as reference points for the BLAC Board to consider. See “The Business Combination — The BLAC M&A Committee’s Reasons for the Approval of the Business Combination”for a detailed discussion on the material findings made in connection with due diligence of OSR Holdings, including with respect to the third -partyvaluation and fair market value reports, and the information contained in the OSR Holdings presentation. May 24, 2023 By email dated May 24, 2023, Mr. Hwang sent to the BLAC Board and OSR Holdings a draft Non -BindingLetter of Intent prepared by BLAC’s counsel K&L Gates with a summary of certain proposed terms and conditions, and a potential timeline for the Business Combination. Mr. Hwang noted in his email that an indicative valuation of OSR Holdings, with the three subsidiaries combined (Vaximm, Darnatein and RMC), had been supported by the fair market value reports secured from the valuation consultants in Korea in connection with OSR Holdings’ share exchange transaction with the three companies. See “The Business Combination — The BLAC M&A Committee’s Reasons for the Approval of the Business Combination — Fair Market Value”for detailed discussions on the fair market value reports on OSR Holdings’ subsidiaries. Although the